Our immunotherapy is designed to be well positioned in rapidly growing markets with high medical needs.

Our immunotherapy is designed to be well positioned in rapidly growing markets with high medical needs.

About

NantKwest is an innovative clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases.

NantKwest is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. The NantKwest “off-the-shelf” activated Natural Killer (NK) platform is designed to destroy cancer and virally infected cells from the body. The safety of our NK cells as well as their activity against a broad range of cancers have been tested in multiple phase 1 clinical trials in the United States, Canada and Europe. In addition to our NK cells capability to be administered in the outpatient setting as an “off-the-shelf” living drug, it serves as a universal cell-based therapy without need for individualized patient matching. Moreover, our NK cell based platform has been bioengineered to incorporate chimeric antigen receptors (CARs) and antibody receptors to potentially further optimize targeting and potency in the therapeutic disease.

NantKwest’s unique NK cell based platform

With the capacity to grow active killer cells as a biological cancer therapy, NantKwest’s NK cells have been designed to induce cell death against cancer or infected cells by multiple modes of action that include:

Direct killing via innate recognition in which NK cells release toxic granules directly into the target (diseased) cell through cell-to-cell contact

Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high binding affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody

Chimeric Antigen Receptor directed killing using the taNK® platform, which includes NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells

All three modes of killing (innate, antibody-mediated, and Chimeric Antigen Receptor directed killing) using the t-haNK™ platform, which is an innovative combination of our haNK® and taNK® platforms in a single cell

Direct killing via innate recognition in which NK cells release toxic granules directly into the target (diseased) cell through cell-to-cell contact

Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high binding affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody

Chimeric Antigen Receptor directed killing using the taNK® platform, which includes NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells

All three modes of killing (innate, antibody-mediated, and Chimeric Antigen Receptor directed killing) using the t-haNK™ platform, which is an innovative combination of our haNK® and taNK® platforms in a single cell

Our haNK®, taNK®, and t-haNK™ platforms have been designed to address certain limitations of T-cell therapies including the reduction of risk of serious “cytokine storms.” As an “off-the-shelf” therapy, NantKwest’s NK cells do not rely on a patient’s own often compromised immune system. In Phase 1 clinical trials in patients with late stage cancer, Nantkwest’s NK cells have been administered as an investigational outpatient infusion therapy without any reported severe side effects to date, even at doses of 10 billion cells.

By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, we believe NantKwest is uniquely positioned to be the premier immunotherapy company and transform medicine by delivering living drugs in a bag and bringing novel NK cell-based therapies to routine clinical care.

+ Learn more about our technology

Leadership

A Culture Committed to Putting Patients First
Our organization cares deeply and works tirelessly to deliver on our mission of improving the lives of patients worldwide. Our talent, scientific knowledge and research capabilities help us to deliver access to innovative, disease-altering therapies to those who need them most. NantKwest’s leadership is responsible for the oversight, strategic direction, operations and success of our company.


CONTACT NANTKWEST
CLICK HERE

NK-92 ®️ CELLS FOR ASSAYS
CLICK HERE